[{"orgOrder":0,"company":"NaviFUS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Inapplicable"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Chang Gung Memorial Hospital","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Inapplicable"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Inapplicable"},{"orgOrder":0,"company":"NaviFUS","sponsor":"NaviFUS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NaviFUS \/ NaviFUS","highestDevelopmentStatusID":"7","companyTruncated":"NaviFUS \/ NaviFUS"}]